Hematology

Top Story

FDA advisory committee expresses support for L-glutamine for sickle cell disease

May 24, 2017

An FDA panel today expressed its support for the approval of L-glutamine powder in the treatment of sickle cell disease.

The Oncologic Drugs Advisory Committee (ODAC) voted 10-3 in favor of Emmaus Medical’s new drug application for oral L-glutamine powder for chronic use in adults and children age 5 years and older with sickle cell disease.

National repository offers ‘endless’ potential for hemophilia research

May 22, 2017
A new national research repository has been created to advance the understanding of hemophilia. My Life, Our Future Research Repository — created by Bloodworks…
In the Journals Plus

Perioperative interruption of direct oral anticoagulants safe, effective

May 19, 2017
Direct oral anticoagulant interruption before a procedure or surgery using a strategy that considered half-life and procedural bleeding risk appeared safe and effective…
In the Journals Plus

Harvoni safe, effective for HCV–infected patients with sickle cell disease

May 18, 2017
Harvoni, a fixed-dose combination of ledipasvir and sofosbuvir, safely and effectively treated hepatitis C virus infection in patients with sickle cell disease…
CME

Polycythemia Vera: Aligning Real World Practices With Current Best Practices

This activity is supported by an independent educational grant from Incyte Corporation.

Ruben A. Mesa, MD, provides practical insights into treating polycythemia vera in this video series. In addition to…
More »
Video

VIDEO: Wide array of therapeutic options in myeloma a ‘wonderful problem’ for hematologists

May 19, 2016
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

CME CNE CPE

Individualized Prophylaxis in Hemophilia

Support for this activity has been made possible through an educational grant from Bayer HealthCare Pharmaceuticals

This program will provide education for hematologists, nurses, pharmacists, and other healthcare providers involved in…
More »
FDA News

FDA advisory committee expresses support for L-glutamine for sickle cell disease

May 24, 2017
An FDA panel today expressed its support for the approval of L-glutamine powder in the treatment of sickle cell disease. The Oncologic Drugs Advisory…

National repository offers ‘endless’ potential for hemophilia research

May 22, 2017
A new national research repository has been created to advance the understanding of hemophilia. My Life, Our Future Research Repository —…

In the Journals Plus

Perioperative interruption of direct oral anticoagulants safe, effective

May 19, 2017
Direct oral anticoagulant interruption before a procedure or surgery using a strategy that considered half-life and procedural bleeding risk appeared…

In the Journals Plus

Harvoni safe, effective for HCV–infected patients with sickle cell disease

May 18, 2017
Harvoni, a fixed-dose combination of ledipasvir and sofosbuvir, safely and effectively treated hepatitis C virus infection in patients with sickle…

CME

Bridging the Gap from Knowledge to Practice in CRPC

May 17, 2017 Expires: 11/17/2017
The selection of therapy for patients with castration-resistant prostate cancer (CRPC) remains challenging. Review answers to some of the most…

This activity is supported by educational funding provided by AbbVie Inc.; Astellas Scientific and Medical Affairs, Inc. and Medivation; and Sanofi US.

FDA News

FDA grants fast track designation to SB-525 for hemophilia A

May 16, 2017
The FDA granted fast track designation to SB-525 for the treatment of hemophilia A, according to the agent’s manufacturer. SB-525 (Sangamo…

In the Journals Plus

Rivaroxaban safe, effective alternative for unprovoked VTE

May 15, 2017
Rivaroxaban conferred lower risk for recurrent deep vein thrombosis and pulmonary embolism than standard treatment in patients with unprovoked venous…

CME

Polycythemia Vera: Aligning Real World Practices With Current Best Practices

May 12, 2017 Expires: 11/12/2017
Ruben A. Mesa, MD, provides practical insights into treating polycythemia vera in this video series. In addition to discussing risk stratification…

This activity is supported by an independent educational grant from Incyte Corporation.

In the Journals Plus

Vena cava filters may have limited influence on incidence of PE

May 10, 2017
Declining use of vena cava filter placement did not correspond with a rise in pulmonary embolism among trauma patients, according to a…

FDA News

FDA grants orphan drug, fast track designations to hemophilia treatments

May 5, 2017
The FDA granted regulatory designations to two hemophilia products manufactured by Sangamo Therapeutics, company officials announced in a press…

More Headlines »
Advertisement
Advertisement